SNPMiner Trials by Shray Alag

SNPMiner SNPMiner Trials (Home Page)

Report for Clinical Trial NCT02888977

Developed by Shray Alag, 2020.
SNP Clinical Trial Gene

An Observatory for Patients Aged 55 Years and Over With Philadelphia Chromosome Positive (Ph+ or BCR-ABL+) Acute Lymphoblastic Leukemia (ALL) and Treated With the Combination of Tyrosine Kinase Inhibitors and Low Intensity Chemotherapy.

The use of imatinib in combination with chemotherapy is now considered as the gold standard for the treatment of Ph+ ALL. The complete remission (CR) rate is 90% versus 20% to 40% with chemotherapy alone. The combination of imatinib, vincristine and dexamethasone is a well tolerated regimen in aged patients and is also associated with a high CR rate of 80% to 90% in patient aged 55 years and over. 2. Dasatinib is indicated as first line therapy in Ph+ ALL. Results from the EWALLPH-01 are supporting the use of dasatinib in combination with low-intensity chemotherapy. A new EWALL-PH-02 study combining nilotinib in combination with low-intensity chemotherapy is currently initiated within the EWALL centers. 3. The EWALL-PH-01 trial is now closed after the recruitment of 71 patients. The activation of the EWALL-PH-02 trial is expected for Q1 2012. Based on the recruitment of the EWALL-PH-01 study it could be anticipated that 50 to 100 patients aged more than 55 years will be diagnosed during this 6 months period of time. In addition, all the EWALL centers are not participating to the EWALL-PH-02 study and thus these centers could be offered to treat patient following the EWALL backbone in addition to imatinib. 4. A minimum data set will be defined in order to collect the data of the patients treated following the EWALL-PH imatinib study. The main recommendation is to follow as close as possible the procedures of the EWALL-PH-01 trial (mutation analysis, MRD follow-up) in order to have a comparable data set. This imatinib treated cohort of patients would be of particular importance in order to better define the potential benefit of using one TKI compared to one other. From the end of the EWALL-PH-01 study recruitment to the initiation of the EWALL-PH-02 study, patients were treated following the common backbone schedule in combination with imatinib or others TKI. Patients not included in clinical trials for other reasons were also offered a treatment with the combination of TKIs and backbone low-intensity chemotherapy. The goal of this observatory retrospective and prospective is to describe the efficacy and the tolerance of the combination of tyrosine kinase inhibitors in combination with low intensity chemotherapy (EWALL backbone) in patients with Ph+ ALL aged 55 years and over.

NCT02888977 Lymphoblastic Leukemia, Acute
MeSH:Leukemia Precursor Cell Lymphoblastic Leukemia-Lymphoma Leukemia, Lymphoid
HPO:Leukemia Lymphoid leukemia

Primary Outcomes

Measure: The primary end-point will be Progression Free Survival (PFS) rate at 12 months

Time: 12 months

Secondary Outcomes

Measure: The proportion of Complete haematological remission

Time: 12 months

Measure: The proportion of Major molecular response defined by a BCR-ABL/ABL ≤ 0.1% in bone marrow

Time: 12 months

Measure: The proportion of Complete molecular response

Time: 12 months

Measure: Event free survival

Time: 12 months

Measure: Relapse free survival

Time: 12 months

Measure: Progression free survival

Time: 12 months

Measure: The proportion of Detection of a T315I or F317 BCR-ABL TK mutation

Time: 12 months

Measure: The proportion of molecular progression defined by the loss of major molecular response

Time: 12 months

Measure: Overall survival

Time: 12 months

Measure: Number of participants with treatment-related adverse events as assessed by CTCAE v4.0

Time: 12 months

Time Perspective: Prospective


There is one SNP


1 T315I

The proportion of Detection of a T315I or F317 BCR-ABL TK mutation. --- T315I ---

HPO Nodes